Anavex Life Sciences Corp. (AVXL) insider have most recently took part in a trading activity. On Sep 18, 2017 Missling Christopher U, President and CEO bought 375 shares having total worth of $1,650 at the price of $4.4 per share, following the transaction a total of 1,008,125 shares owned by Missling Christopher U. Before this latest buy, Missling Christopher U purchased AVXL at 11 other times during the past twelve months, for a total investment of $19,196 at an average of $4.33 per share.
The stock has experienced a total of 11 insider trades in the past three months. These trades include 11 buy trades. Furthermore, over the past 12 months , the stock was traded 11 times by insiders. an employee of the company was the buyer in 11 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Anavex Life Sciences Corp. (AVXL) traded down 1.13% on Sep 18, 2017, hitting $4.38. 216,558 shares of the company’s stock traded hands. Anavex Life Sciences Corp. has a 52 week low of $2.5 and a 52 week high of $7.73. The company’s market cap is $112 million.
Anavex Life Sciences Corp. (AVXL) last announced its earnings results on Aug 7, 2017. The company reported -0.09 earnings per share (EPS) for the quarter, same as the consensus estimate of -0.09. During the same quarter in the previous year, the company posted -0.06 earnings per share.
|earnings per share||-0.09||-0.04||-0.08||-0.18|
Anavex Life Sciences Corporation is a pharmaceutical company, which is engaged in the development of drug candidates. The company’s portfolio involves new sigma receptor compounds (ligands) in the preclinical stage that target neurodegenerative diseases and cancer. Its drug candidate ANAVEX 2-73, targeting Alzheimer’s disease (AD), is expected to enter first Human Clinical Trials (HCT) in early 2010. Scale-up manufacturing of ANAVEX 2-73 has been completed and Forenap Pharma EURL has been contracted to carry out its phase 1 clinical trials. It intends to further develop compounds in earlier preclinical phases, which target diseases like diabetes, depression, neuropathic pain and various types of cancer and continue to develop and expand its SIGMACEPTOR platform. Its SIGMACEPTOR Discovery Platform has resulted in and continues to generate small molecule drug candidates with unique modes of action, by making use of sigma receptors, which represent potential targets for therapeutic developments in combating many human diseases (such as AD, depression, epilepsy and cancer). Its SIGMACEPTOR(tm)-C program leverages the unique properties of sigma-1 and/or sigma-2 receptor ligands, which allows creating a potent class of promising drug candidates designed to combat various types of solid cancer. Sigma receptors are expressed in different tumor cell types and binding by appropriate sigma-1 and/or sigma-2 ligands induce selective apoptosis. ANAVEX 7-1037 is designed for the treatment of prostate cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. It has also been shown to selectively kill human cancer cells without affecting normal/healthy cells and also to suppress tumor growth in immune-deficient mice models. Scientific publications emphasize the promise of sigma receptor ligands, highlighting the fact that these ligands stop tumor growth and induce selective cell death in various tumor cell lines, including leukemia, melanoma and cancers of the colon, breast, prostate, lung, brain, ovary and kidney. The company provides remedies and treatments for Alzheimer’s disease and Cancer Disease. In pre-clinical studies conducted in France, and in Greece, ANAVEX 2-73 demonstrated anti-amnesic and neuroprotective properties. ANAVEX 2-73 may offer a disease-modifying approach in Alzheimer’s disease (AD) by using ligands that activate sigma-1 receptors. ANAVEX 19-144 is the sole active metabolite of ANAVEX 2-73. Like ANAVEX 2-73, preclinical data reveals that ANAVEX 19-144 exhibits significant anti-amnesic, neuroprotective and anticonvulsant properties in a variety of in vitro systems and specialized animal models. ANAVEX 1-41 is a sigma-1 agonist. Three approaches are mainly used to treat central nervous system diseases and cancer: Neurosurgery or invasive techniques; Pharmacological technique
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018